fightaging.org

Fight Aging! is all three at once, but the mix matters if you are deciding whether to follow it. It is primarily an advocacy platform for rejuvenation biotechnology that doubles as a research digest, with news commentary layered on top. The site's own description frames it as "the science of rejuvenation biotechnology. Advocacy for longer, healthier lives." If you want consumer anti-aging product coverage, this is not the source. If you want ongoing commentary on the science and the longevity industry, with a clear point of view, it fits.

What the site actually publishes

The homepage evidence shows a stream of dated posts, each tied to a specific paper or development, with a byline ("Posted by Reason") and comment threads attached. Recent examples include:

• "A Conservative View of the Geroscience Endeavor"
• "Possible Approaches to Engineering Better Therapeutic Delivery of Mitochondria"
• "The Geomagnetic Field Influences Mitochondrial Function in Complex Ways"
• "Don't View mTOR as a Single Pharmaceutical Target, as Context Matters"
• "The Peptide Catestatin Reduces Tau Pathology in Mice"

Two structural features stand out. First, posts link to open-access papers and often summarize them. Second, comments are enabled, so the site functions partly as a discussion venue rather than a one-way feed.

Where it sits among longevity information sources

The distinguishing trait is that it does not just report findings, it argues about how much weight they deserve.

The evidence-strength argument, as the site makes it

The clearest illustration of the site's editorial position comes from its own commentary on how the longevity industry gets lumped together. The excerpt draws a sharp line between two categories of therapy:

• NAD+ upregulation — described as having unreliable animal data, small effect size, and a long history of failed human trials across a range of conditions.
• Senolytics to clear senescent cells — described as having reliable and extensive animal data, a large effect size for reversing age-related conditions, and mixed data from a small number of early human trials.

The site calls treating these as equivalent "a category error that is becoming common," and notes they emerge from "very different philosophies of development." This is the core editorial move: sorting claims by the strength of the evidence behind them rather than by how promising they sound.

What this means for a reader

If you are deciding whether to track Fight Aging!, the practical implications are:

• You will get interpretation, not just aggregation. Expect the author to tell you which results he thinks are solid and which are not.
• You will get a pro-research stance. The framing is that "one doesn't win victories by refraining from participation," so the site is not neutral about whether the field should proceed.
• You will encounter skepticism aimed at the field itself. The criticism is directed at overclaiming and at conflating weak and strong evidence, not at the goal of extending healthy life.
• You will need some tolerance for scientific context. Posts reference pathways, mechanisms, and specific papers rather than translating everything into lifestyle advice.

When it is the right source, and when it is not

Choose Fight Aging! if you want a running, opinionated digest of rejuvenation research and industry developments, and you value having evidence quality sorted for you. Look elsewhere if you want neutral wire-style summaries, or if you are shopping for supplements and consumer products — the site's own framing puts it on the science and advocacy side, not the product side. The comment threads are worth checking if you want to see where informed readers push back on the author's read.

Fight Aging! argues that the longevity industry's biggest communication problem is not hype about any single therapy, but the habit of grouping very different interventions under one label. In the site's own words, lumping approaches together is "a category error that is becoming common." The practical takeaway for readers: judge each therapy by its own evidence base — reliability of animal data, effect size, and human trial results — rather than by the fact that it appears in a longevity headline.

The core distinction the site draws

The site's editorial position, stated in its coverage of a broad geroscience review, is that a survey which places NAD+ upregulation and senolytics under one heading misleads readers. Its reasoning rests on three separate comparisons:

• Reliability of animal data. Senolytics to clear senescent cells are described as having "reliable and extensive animal data." NAD+ upregulation is described as having "unreliable animal data."
• Effect size. Senolytics show a "large effect size for reversal of age-related conditions." NAD+ upregulation shows a "small effect size."
• Human trial history. NAD+ upregulation has a "long history of failed human trials for a range of conditions." Senolytics have "mixed data from only a few early human trials."

The site also notes that these therapies "emerge from very different philosophies of development" — meaning the difference is not just in results but in how each field decides what counts as sufficient proof before moving forward.

Why "promising" and "proven" are not the same claim

Fight Aging! frames the disagreement as a spectrum rather than a binary. On one end is what it calls an "archly conservative viewpoint," which links academic caution ("this thing you are doing has not yet been proven beyond all doubt to work") to industry caution ("this thing you are doing has not yet been proven beyond all doubt to generate profit"). Both positions treat the question — can human aging be slowed or reversed as it can in laboratory species? — as an unfinished test.

The site's own position is that this caution is a choice with costs: "one doesn't win victories by refraining from participation." But it does not resolve that tension by treating all candidates as equally likely to succeed. Instead it separates two questions:

1. Is there a plausible mechanism and some supporting data? (Many lines of work pass this bar.)
2. How much additional healthy life can this actually provide in humans? (For most, still unknown.)

The site states that for many lines of work, "the only remaining question is how much additional life they can provide to members of our own species." That is a claim about magnitude, not about whether the approach works at all — and it is a much weaker claim than "proven."

A practical reading checklist

When you encounter a longevity therapy in the news, apply the same three dimensions the site uses:

A therapy can be genuinely promising on mechanism while still lacking the human evidence to support strong claims. The site's objection is to collapsing those two states into one.

What this means for following the longevity industry

Fight Aging! does not ask readers to dismiss the industry — it explicitly notes that "a great many other people, scientists, entrepreneurs, patients, and patient advocates, are less conservative," and that this is why the field exists. Its ask is narrower: keep the categories separate. A broad review that surveys "everything that might fall into the purview of the diverse longevity industry" is useful as a map, but not as a ranking. Treat each entry as its own evidence case, and check which of the three dimensions above it actually satisfies before treating it as comparable to a therapy with extensive, replicated animal data and large effect sizes.

Fight Aging! (fightaging.org) is a news and commentary site focused on the science of rejuvenation biotechnology and advocacy for longer, healthier lives. It is aimed at readers who want ongoing, opinionated coverage of aging research and the longevity industry rather than general health or lifestyle content. If you are looking for a running feed of research summaries, industry developments, and critical commentary on how aging science is framed, this site is built for that purpose.

What the site is about

The site's own description is "The science of rejuvenation biotechnology. Advocacy for longer, healthier lives." In practice, that means:

• Rejuvenation biotechnology — research and therapies aimed at repairing or reversing the biological damage of aging, not just managing individual age-related diseases.
• Longevity science — the biology of aging, including conserved molecular pathways that can be modulated pharmacologically.
• Advocacy — a stated position that aging should be treated as a target for medical intervention, and that longer, healthier lives are a goal worth pursuing.

What kind of content you will find

The site publishes articles and commentary, often built around open-access research and reviews. From the page evidence, recent items include:

The excerpt also shows the site's editorial voice: it argues that lumping very different approaches under one "longevity industry" heading is a category error. It contrasts NAD+ upregulation (described as having unreliable animal data, small effect size, and failed human trials) with senolytics (described as having reliable and extensive animal data and large effect size for reversing age-related conditions). That kind of evidence-weighted comparison is characteristic of the site's commentary.

Who it is for

• Readers who want to follow aging research and the longevity industry at a level between press releases and primary papers.
• People interested in rejuvenation biotechnology as a field, including its scientific debates and its advocacy side.
• Anyone trying to judge how strong the evidence is for different proposed anti-aging approaches, since the site frequently compares evidence quality across therapies.

What to expect in tone and scope

The content is explanatory and argumentative rather than neutral news reporting. It takes positions — for example, that aging can potentially be slowed or reversed in humans as it has been in laboratory species, and that waiting for certainty before participating is not how victories are won. It also critiques how the field and industry categorize their own work.

If you want a site that treats aging as a medical problem to be solved and comments critically on the science and business around that goal, Fight Aging! matches that description. If you want neutral, broad health coverage or clinical guidance, this is not that kind of source.

On Fight Aging!, rejuvenation biotechnology is the goal — using biotechnology to repair or reverse the damage that aging causes — while geroscience is the research field that studies aging itself as the biology behind chronic disease. The site treats the two as linked: geroscience supplies the understanding of aging mechanisms, and rejuvenation biotechnology is the applied program that tries to intervene in them. This framing matters because it separates the site's subject matter from ordinary "anti-aging" marketing: the focus is on measurable mechanisms and therapies under development, not on supplements or lifestyle claims.

Geroscience: aging as the root risk factor

The site's own description calls it "the science of rejuvenation biotechnology" and "advocacy for longer, healthier lives." In the article excerpt on the homepage, aging is described as "the strongest risk factor for chronic diseases such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders." That is the core geroscience premise: rather than treating each age-related disease separately, geroscience asks whether the underlying biology of aging can be targeted, and whether doing so shifts multiple diseases at once.

On Fight Aging!, geroscience shows up as coverage of conserved molecular pathways — the mechanisms that are similar across species and that laboratory work has linked to aging. The homepage headings illustrate the range: mTOR signaling ("Don't View mTOR as a Single Pharmaceutical Target, as Context Matters"), mitochondrial function, tau pathology in mice, and peptide research. These are mechanism-level topics, not product recommendations.

Rejuvenation biotechnology: the applied side

Where geroscience is the study of aging, rejuvenation biotechnology is the attempt to act on it. The site's excerpt groups potential therapies under the longevity industry and notes that "many lines of work that lead to potential rejuvenation therapies are highly promising." The recurring question it poses is practical: can aging "be slowed or reversed in a practical way in humans as it can in laboratory species?"

A key editorial point on the site is that not all approaches deserve equal weight. The excerpt argues it is a mistake to treat NAD+ upregulation and senolytics as equivalent:

That comparison is the site's own framing, and it shows how the terms function in practice: "rejuvenation biotechnology" is a category, and individual therapies inside it are judged by the strength of their evidence.

How the two concepts connect across the site's topics

The site uses these terms to tie together otherwise separate subjects:

• Drugs and metabolic pathways — pharmacological modulation of conserved pathways, as in the review "Geroprotective Effects of Drugs Modulating Metabolic Pathways."
• Cell-level therapies — clearing senescent cells, the example the site rates most highly on evidence.
• Organelle and signaling research — mitochondria, mTOR, and related mechanisms.
• Disease-specific findings — for example, the peptide catestatin reducing tau pathology in mice.

The through-line is that each topic is presented as a possible intervention point in aging biology, with the site asking how strong the evidence is and how large the effect might be.

How this differs from ordinary "anti-aging" content

The distinction is mainly about what counts as evidence and what is being claimed:

• Mechanism over marketing. The site discusses pathways, animal models, and trial results rather than promising personal outcomes.
• Explicit evidence grading. As the NAD+ versus senolytics comparison shows, approaches are not treated as interchangeable.
• A stated uncertainty. The excerpt acknowledges a "conservative view" that asks whether aging can in fact be slowed or reversed in humans, and notes that "the future is ever uncertain."
• Advocacy, not neutrality. The site describes itself as advocacy for longer, healthier lives, so it is not a disinterested news source — but its arguments are framed around scientific evidence and development philosophy.

What this means for reading the site

If you encounter "rejuvenation biotechnology" on Fight Aging!, read it as the applied goal of intervening in aging damage. If you encounter "geroscience," read it as the research base that identifies what might be intervened in. When the site compares therapies, expect it to weigh animal data, effect size, and human trial results separately — and expect it to push back when very different approaches are lumped together under one longevity-industry heading.